MONTREAL, QUEBEC , September 9, 2022 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the third quarter ended July 31, 2022 on Tuesday September 13, 2022 after market close. The Company will host a conference call to discuss those results and highlights on Wednesday September 14, 2022 at 8.30am (ET).

Conference ID:                  38670463

Date:                                 Wednesday, September 14, 2022

Time:                                 8:30am ET

Dial-in numbers:                1-888-664-6392 or 416-764-8659

Audio replay numbers:       1-888-390-0541 or 416-764-8677

Replay code:                     670463#

A live audio webcast of the conference call will be available via:

https://app.webinar.net/bKVqJ5MJrgD

About Valeo Pharma Inc.

Valeo Pharma is a fast growing Canadian pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respiratory/Allergy, Ophthalmology and Hospital Specialty Products. Headquartered in Kirkland, Quebec Valeo Pharma has all the required capabilities and the full infrastructure to register and properly manage its growing product portfolio through all stages of commercialization. For more information, please visit www.valeopharma.com and follow us on LinkedIn and Twitter.

Forward Looking Statements

This press release contains forward-looking statements about Valeo’s objectives, strategies and businesses that involve risks and uncertainties. These statements are “forward-looking” because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate.

For more information:

Steve Saviuk

CEO

514-693-8830

saviuk@valeopharma.com

or

Luc Mainville
Senior Vice-President and Chief Financial Officer       
514-693-8854
mainville@valeopharma.com

or

Frederic Dumais

Director, Communications and Investor Relations

514-782-8803

dumais@valeopharma.com